| Symbol | IVA |
|---|---|
| Name | INVENTIVA S.A. |
| Sector | HEALTH CARE |
| Region | Europe |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 50 RUE DE DIJON, DAIX, 21121, France |
| Telephone | +33 380447500 |
| Fax | — |
| — | |
| Website | https://www.inventivapharma.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001756594 |
| Description | Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the companys operations are in France. Additional info from NASDAQ: |
Inventiva renforce son équipe de direction à l’approche des résultats de Phase 3 du lanifibranor
Read moreInventiva Strengthens Leadership Team Ahead of Expected Phase 3 Data Readout of Lanifibranor
Read moreInventiva Strengthens Leadership Team Ahead of Expected Phase 3 Data Readout of Lanifibranor
Read moreInventiva renforce son équipe de direction à l’approche des résultats de Phase 3 du lanifibranor
Read moreInventiva annonce ledépôt de son Document d’EnregistrementUniversel 2025 et de son Rapport Annuel 2025(« Form 20-F »)
Read more